A detailed history of New Edge Advisors, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 247 shares of CSTL stock, worth $6,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247
Holding current value
$6,748
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$26.52 - $34.67 $6,550 - $8,563
247 New
247 $6,000
Q4 2023

Feb 13, 2024

BUY
$12.19 - $22.43 $3,047 - $5,607
250 New
250 $5,000
Q4 2022

Feb 14, 2023

BUY
$18.08 - $30.0 $7,195 - $11,940
398 New
398 $9,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $718M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.